表紙:副甲状腺機能亢進症 (HPT)、高リン血症 (HP)、高カリウム血症 (HK) を含む慢性腎臓病 (CKD) :2030年までの疫学予測
市場調査レポート
商品コード
1005541

副甲状腺機能亢進症 (HPT)、高リン血症 (HP)、高カリウム血症 (HK) を含む慢性腎臓病 (CKD) :2030年までの疫学予測

Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) - Epidemiology Forecast to 2030

出版日: | 発行: GlobalData | ページ情報: 英文 48 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=129.43円
副甲状腺機能亢進症 (HPT)、高リン血症 (HP)、高カリウム血症 (HK) を含む慢性腎臓病 (CKD) :2030年までの疫学予測
出版日: 2021年04月30日
発行: GlobalData
ページ情報: 英文 48 Pages
納期: 即納可能 即納可能とは
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性腎臓病(CKD)または慢性腎疾患は、時間の経過とともに徐々に腎機能が低下することを特徴とする状態です。初期の段階では、CKDはほとんど無症状の状態で、腎臓に損傷を与え、時間の経過とともに腎機能の喪失につながり、病気が進行するにつれて、症状は悪化し、最終的には腎不全に至ります。

7つの主要市場(米国、フランス、ドイツ、イタリア、スペイン、英国、および日本)において、CKDの診断された症例数は、年間成長率(AGR)1.01%で拡大する見通しで、2020年の856万9,869例から2030年には944万881例に増加すると予測されています。2030年の7つの主要市場において米国が診断された有病率が最も高く425万3,149例となり、イタリアは33万9,208例と最も少なくなっています。診断された有病率とCKDの有病率が増加しているのは、各市場の人口動態によるものである考えられています。

当レポートは、副甲状腺機能亢進症(HPT)、高リン血症(HP)、高カリウム血症(HK)を含む慢性腎臓病(CKD)について調査しており、7つの主要市場(米国、フランス、ドイツ、イタリア、スペイン、英国、および日本)の動向、CKDのリスク要因、併存疾患、世界の疫学動向および予測などの情報を提供しています。

目次

目次

第1章 CKD-副甲状腺機能亢進症、高リン血症、高カリウム血症:エグゼクティブサマリー

  • 触媒
  • 関連レポート
  • 今後の報告

第2章 疫学

  • 病歴
  • 危険因子と併存疾患
  • 世界および過去の動向
  • 7つの主要市場の予測調査手法
    • 情報源
    • 予測の前提条件と方法
    • 予測の前提条件と方法:CKDの診断症例数-7つの主要市場
    • 予測の前提条件と方法:CKDの総症例数
    • 予測の前提条件と方法:ステージ別のCKDの診断と症例の合計
    • 透析依存症に基づくCKD診断症例数
    • 透析依存性および非依存性CKD症例における副甲状腺機能亢進症を伴うCKDの診断症例数
    • 透析依存性および非透析依存性CKD症例における高リン血症を伴うCKDの診断症例数
    • 透析依存性および非透析性CKD症例における高カリウム血症を伴うCKDの診断症例数
  • 慢性腎臓病の疫学予測副甲状腺機能亢進症、高リン血症、高カリウム血症(2020-2030)
    • CKDの一般的な診断症例数
    • 年齢別:CKD診断症例数
    • 性別:CKD診断症例数
    • ステージ別:CKD診断症例数
    • 透析依存症に基づくCKD診断症例数
    • 透析依存性および非透析性CKD症例における副甲状腺機能亢進症を伴うCKD診断症例数
    • 透析依存性および非依存性CKD症例における高リン血症を伴うCKD診断症例数
    • 透析依存性および非依存性CKD症例における高カリウム血症を伴うCCKD診断症例数
    • CKD総症例数
    • 年齢別:CKD総症例数
    • 性別:CKD総症例数
    • ステージ別:CKD総症例数
  • 討論
    • 疫学予測の洞察
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第3章 付録

  • 書誌
  • 著者について
    • 疫学者
    • レビュアー
    • 治療分析および疫学の世界におけるディレクター
    • ヘルスケアオペレーションおよび戦略の世界の主要およびEVP
  • お問い合わせ
図表

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: KDIGO Classification of CKD
  • Table 4: Risk Factors and Comorbidities for CKD

List of Figures

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of CKD, Both Sexes, N, Ages ≥18 Years, 2020 and 2030
  • Figure 2: 7MM, Total Prevalent Cases of CKD, Both Sexes, N, Ages ≥18 Years, 2020 and 2030
  • Figure 3: 7MM, Diagnosed Prevalence of CKD, Men and Women, %, Ages ≥18 Years, 2020
  • Figure 4: 7MM, Total Prevalence of CKD, Men and Women, %, Ages ≥18 Years, 2020
  • Figure 5: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD
  • Figure 6: 7MM, Sources Used to Forecast the Diagnosed and Total Prevalent Cases of CKD by Stage
  • Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD with Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases
  • Figure 9: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of CKD
  • Figure 10: 7MM, Diagnosed Prevalent Cases of CKD, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 11: 7MM, Diagnosed Prevalent Cases of CKD by Age, N, Both Sexes, 2020
  • Figure 12: 7MM, Diagnosed Prevalent Cases of CKD by Sex, N, Ages ≥18 Years, 2020
  • Figure 13: 7MM, Diagnosed Prevalent Cases of CKD by Stage, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 14: 7MM, Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 15: 7MM, Diagnosed Prevalent Cases of CKD with Hyperparathyroidism, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 16: 7MM, Diagnosed Prevalent Cases of CKD With Hyperphosphatemia, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 17: 7MM, Diagnosed Prevalent Cases of CKD with Hyperkalemia, N, Both Sexes, ≥18 Years, 2020
  • Figure 18: 7MM, Total Prevalent Cases of CKD, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 19: 7MM, Diagnosed Total Cases of CKD by Age, N, Both Sexes, 2020
  • Figure 20: 7MM, Total Prevalent Cases of CKD by Sex, N, Ages ≥18 Years, 2020
  • Figure 21: 7MM, Total Prevalent Cases of CKD by Stage, N, Both Sexes, Ages ≥18 Years, 2020
目次
Product Code: GDHCER271-21

Chronic kidney disease (CKD), or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. In the early stages, CKD is a largely asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time (Centers for Disease Control and Prevention, 2019). As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2019). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered as the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013).

In the 7MM, the diagnosed prevalent cases of CKD are expected to increase from 8,569,869 cases in 2020 to 9,440,881 cases in 2030, at an Annual Growth Rate (AGR) of 1.01%. In 2030, the US will have the highest number of diagnosed prevalent cases of CKD in the 7MM, with 4,253,149 diagnosed prevalent cases, whereas Italy will have the fewest diagnosed prevalent cases with 339,208 cases. In the 7MM, the total prevalent cases of CKD are expected to increase from 97,176,505 cases in 2020 to 107,283,608 cases in 2030, at an AGR of 1.04%. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases and total prevalent cases of CKD to population dynamics in each market.

Scope

  • This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed and total prevalent cases of CKD. The diagnosed and total prevalent cases of CKD are segmented by age (18 years and older), sex, and stage. The diagnosed prevalent cases of CKD are segmented based on dialysis-dependent and non-dialysis-dependent cases.
  • The dialysis dependent cases are further segmented by hemodialysis-dependent and peritoneal dialysis-dependent. Additionally, the diagnosed prevalent cases of CKD were further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases. This epidemiology forecast for CKD is supported by data obtained from peer-reviewed articles and population-based studies.
  • The CKD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The CKD Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CKD market.
  • Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for CKD therapeutics in each of the markets covered.
  • Understand magnitude of CKD by stage, hemodialysis-dependent and peritoneal dialysis-dependent; hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases of CKD.

Table of Contents

Table of Contents

1 CKD - Hyperparathyroidism, Hyperphosphatemia, and Hyperkalemia: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 7MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CKD - 7MM
    • 2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of CKD
    • 2.4.5 Forecast Assumptions and Methods: Diagnosed and Total Prevalent Cases of CKD by Stage
    • 2.4.6 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
    • 2.4.7 Diagnosed Prevalent Cases of CKD with Hyperparathyroidism Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
    • 2.4.8 Diagnosed Prevalent Cases of CKD with Hyperphosphatemia Among Dialysis Dependent and Non-dialysis Dependent CKD Cases
    • 2.4.9 Diagnosed Prevalent Cases of CKD with Diagnosed Prevalent Cases of CKD with Hyperkalemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
  • 2.5 Epidemiological Forecast for Chronic Kidney Disease Hyperparathyroidism, Hyperphosphatemia and Hyperkalemia (2020-2030)
    • 2.5.1 Diagnosed Prevalent Cases of CKD
    • 2.5.2 Age-Specific Diagnosed Prevalent Cases of CKD
    • 2.5.3 Sex-Specific Diagnosed Prevalent Cases of CKD
    • 2.5.4 Diagnosed Prevalent Cases of CKD by Stage
    • 2.5.5 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
    • 2.5.6 Diagnosed Prevalent Cases of CKD with Hyperparathyroidism Among Dialysis-Dependent and Non-dialysis-Dependent CKD Cases
    • 2.5.7 Diagnosed Prevalent Cases of CKD with Hyperphosphatemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
    • 2.5.8 Diagnosed Prevalent Cases of CKD With Hyperkalemia Among Dialysis-Dependent and Non-Dialysis-Dependent CKD Cases
    • 2.5.9 Total Prevalent Cases of CKD
    • 2.5.10 Age-Specific Total Prevalent Cases of CKD
    • 2.5.11 Sex-Specific Total Prevalent Cases of CKD
    • 2.5.12 Total Prevalent Cases of CKD by Stage
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us